Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)